T2 Biosystems, Inc. reiterated revenue guidance for the full year 2024. For the year, the company expects total sepsis and related product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 million in 2023. The Company?s 2024 revenue guidance consists entirely of sepsis product revenue and does not include potential sales of the T2Biothreat Panel or the T2Lyme Panel.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.64 USD | 0.00% | +52.64% | -10.12% |
05-15 | Sector Update: Health Care Stocks Advance Late Wednesday Afternoon | MT |
05-15 | T2 Biosystems Shares Rise After CRG Servicing Ups Stake | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.12% | 86.66M | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |
- Stock Market
- Equities
- TTOO Stock
- News T2 Biosystems, Inc.
- T2 Biosystems, Inc. Reiterates Revenue Guidance for the Full Year 2024